

Spyridon Sifis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1563784/publications.pdf>

Version: 2024-02-01

46
papers

1,099
citations

567281

15
h-index

454955

30
g-index

47
all docs

47
docs citations

47
times ranked

898
citing authors

#	ARTICLE	IF	CITATIONS
1	How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices. <i>Schizophrenia Bulletin</i> , 2022, 48, 27-36.	4.3	7
2	Family interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2022, 9, 211-221.	7.4	47
3	Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2022, 48, 643-654.	4.3	35
4	Atypical antipsychotics in multiple sclerosis: A review of their in vivo immunomodulatory effects. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103522.	2.0	4
5	Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. <i>Lancet</i> , 2022, 399, 824-836.	13.7	88
6	Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. <i>Molecular Autism</i> , 2022, 13, 10.	4.9	36
7	Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis. <i>Lancet Psychiatry</i> , 2022, 9, 232-242.	7.4	15
8	Confidence of evidence should be considered in ranking of treatments in the network meta-analysis – Authors' reply. <i>Lancet Psychiatry</i> , 2022, 9, e16.	7.4	0
9	Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2022, 48, 738-740.	4.3	13
10	Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia. <i>BMC Psychiatry</i> , 2022, 22, .	2.6	2
11	Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in an Italian Sample of Patients with Stable Schizophrenia and Bipolar Spectrum Disorders. <i>Brain Sciences</i> , 2022, 12, 891.	2.3	1
12	Antipsychotic drugs: from –major tranquilizers– to Neuroscience-based-Nomenclature. <i>Psychological Medicine</i> , 2021, 51, 522-524.	4.5	10
13	Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 672-681.	4.3	4
14	Second-to-Fourth Digit Ratio (2D:4D) in Psychiatric Disorders: A Systematic Review of Case-control Studies. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 26-45.	2.0	17
15	Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis. <i>Schizophrenia Research</i> , 2021, 229, 3-11.	2.0	7
16	Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies. <i>Behavioural Brain Research</i> , 2021, 404, 113168.	2.2	11
17	Assessment of the Safety Signal for the Abuse Potential of Pregabalin and Gabapentin Using the FAERS Database and Big Data Search Analytics. <i>Frontiers in Psychiatry</i> , 2021, 12, 640264.	2.6	9
18	Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models. <i>Frontiers in Immunology</i> , 2021, 12, 677879.	4.8	20

#	ARTICLE	IF	CITATIONS
19	Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4769-4779.	2.4	16
20	Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder. <i>Brain Sciences</i> , 2021, 11, 908.	2.3	4
21	A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders. <i>European Neuropsychopharmacology</i> , 2021, 48, 49-88.	0.7	29
22	The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of in vitro and in vivo Models. <i>Current Pharmaceutical Design</i> , 2021, 27, 2387-2397.	1.9	3
23	Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials. <i>Systematic Reviews</i> , 2021, 10, 214.	5.3	5
24	Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia. <i>JAMA Psychiatry</i> , 2021, 78, 1238.	11.0	44
25	Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review. <i>Translational Psychiatry</i> , 2021, 11, 487.	4.8	61
26	Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis. <i>Schizophrenia Research</i> , 2021, 237, 20-25.	2.0	22
27	Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2021, 8, 969-980.	7.4	114
28	Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia—Reply. <i>JAMA Psychiatry</i> , 2021, , .	11.0	0
29	Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 6003-6012.	0.7	5
30	Antipsychotic drugs <i>v.</i> barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2020, 50, 2622-2633.	4.5	6
31	Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. <i>American Journal of Psychiatry</i> , 2020, 177, 342-353.	7.2	137
32	Levetiracetam as preventive treatment in adults with migraine: an up-to-date systematic review and quantitative meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 161-174.	1.9	6
33	M201. MODERATORS OF WEIGHT GAIN IN RANDOMIZED CONTROLLED TRIALS OF SCHIZOPHRENIA — A META-REGRESSION ANALYSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S212-S213.	4.3	0
34	Shared decision making, aggression, and coercion in inpatients with schizophrenia. <i>European Psychiatry</i> , 2020, 63, e90.	0.2	7
35	The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database. <i>Frontiers in Neurology</i> , 2020, 11, 1012.	2.4	14
36	Maintenance treatment with antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2020, 2020, CD008016.	2.8	56

#	ARTICLE	IF	CITATIONS
37	Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. <i>Molecular Autism</i> , 2020, 11, 66.	4.9	40
38	T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS – PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK-METAANALYSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S308-S308.	4.3	0
39	Combining big data search analytics and the FDA Adverse Event Reporting System database to detect a potential safety signal of mirtazapine abuse. <i>Health Informatics Journal</i> , 2020, 26, 2265-2279.	2.1	7
40	The Added Value of Liquid Antipsychotics: The Case of Quetiapine. <i>Current Clinical Pharmacology</i> , 2019, 14, 101-107.	0.6	5
41	Tachyphylaxis to the Sedative Action of Mirtazapine. <i>American Journal of Case Reports</i> , 2018, 19, 410-412.	0.8	2
42	Nonmedical Use of Prescription Drugs among Medical Students and the Relationship With Illicit Drug, Tobacco, and Alcohol Use. <i>Substance Abuse: Research and Treatment</i> , 2018, 12, 117822181880229.	0.9	11
43	Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. <i>Current Neuropharmacology</i> , 2018, 16, 1210-1223.	2.9	98
44	Prevalence of Cannabis Use Among Medical Students: A Systematic Review and Meta-analysis. <i>Substance Abuse: Research and Treatment</i> , 2018, 12, 117822181880597.	0.9	27
45	Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance–pharmacodynamic study. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2405-2414.	2.4	30
46	Nogo receptor complex expression dynamics in the inflammatory foci of central nervous system experimental autoimmune demyelination. <i>Journal of Neuroinflammation</i> , 2016, 13, 265.	7.2	24